Nourish Raises $100M Series C to Reverse Chronic Disease with AI-Native Metabolic Clinic

Key Takeaways

• Nourish raised $100M Series C, bringing total funding to $215M.
• AI‑native clinic achieves 8% weight loss and $2,000 yearly savings per patient.
• Over 10,000 dietitians support a network covering 200M Americans.
• Partners include hundreds of health plans and 250+ health systems.
• GLP‑1 meds boost demand, but nutrition support drives long‑term adherence.

Pulse Analysis

Chronic disease remains the dominant cost driver in U.S. healthcare, accounting for roughly $5 trillion in annual spending. As insurers and employers scramble for solutions that move beyond reactive treatment, digital health platforms that combine data‑rich AI with clinical expertise are gaining traction. Nourish’s recent $100 million Series C underscores investor confidence that AI‑native metabolic care can address both the clinical and financial dimensions of this crisis, especially as GLP‑1 medications fuel demand for comprehensive, sustainable weight‑management programs.

At the core of Nourish’s offering is a hybrid model that pairs virtual Registered Dietitians with proprietary AI health agents. Patients receive personalized nutrition plans, lab monitoring, and medication management—including GLP‑1 prescribing—delivered through a mobile app that drives daily engagement. Reported outcomes, such as an average 8% weight reduction, a 1.3‑point A1C drop, and a $2,000 per‑patient annual cost saving, illustrate how algorithm‑guided behavior change can translate into tangible health‑plan savings. The AI copilot also streamlines provider workflows by surfacing real‑time insights, reducing administrative overhead and improving care quality.

The capital raise positions Nourish to accelerate network expansion, targeting over 10,000 dietitians and deeper integration with more than 250 health systems. By cementing relationships with major health plans and employers, the company can scale its model to the 200 million Americans already covered by participating insurers. As competitors vie for a share of the burgeoning metabolic‑care market, Nourish’s blend of clinical depth, AI scalability, and proven cost‑effectiveness gives it a distinct strategic advantage, potentially reshaping how chronic disease is managed in the United States.